EUVIMEDEUVIMED entdecken
Crossref

PRKCA and ABCB1 dual-enriched exosomes are key drivers of drug resistance in chronic myeloid leukemia

Fei Li, Jin-Fei Lin, Peng Tian, Haisheng Chen, Qian Yang, Qiqi Guo, Jiasheng Wang, Yue He, Junru Chen, Xiaojian Hu, Chunmou Li, Weitong Mai und 6 weitere

Drug Resistance Updates · 2026

DOI: 10.1016/j.drup.2026.101421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Fei Li und 17 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China. Hauptthemen laut MEDLINE: Exosomes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Resistance, Neoplasm, Protein Kinase C-alpha. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Drug resistance frequently results in treatment failure for leukemia and leads to the progression of chronic myeloid leukemia (CML) into an accelerated or blast phase. An increasing number of CML cases exhibit reduced responsiveness or are refractory to tyrosine kinase inhibitors and chemotherapeutic drugs. Exosomes, as intercellular communication carriers, have been shown to participate in various forms of tumor drug resistance, but their role and mechanisms in CML drug resistance have not yet been fully investigated. METHODS: Exosomes were isolated from the cell culture medium or plasma using ultracentrifugation. RNA sequencing, LC-MS proteomics, Western blot, molecular docking, co-immunoprecipitation, cell viability assay, and flow cytometry analysis were carried out to examine the mechanisms of exosomes in CML drug resistance. Cell line-derived and patient-derived xenografts were estimated to verify the mechanisms of exosomes in CML drug resistance in vivo. Clinical samples from CML patients were used to analyze the predictive potential of exosomes in CML drug resistance. RESULTS: Drug-resistant CML cell-derived exosomes promote multifaceted resistance to imatinib and doxorubicin by directly disseminating the ATP-binding cassette subfamily B member 1 (ABCB1) efflux pump to initially sensitive cells and indirectly upregulating ABCB1 expression, enhancing drug expulsion and resistance. The specific binding regions between ABCB1 with protein kinase C-alpha (PRKCA) that is required for dual-enriched exosomal packaging and ABCB1-mediated resistance. We identified myristoylated alanine-rich C kinase substrate (MARCKS) regulation of PRKCA is an essential prerequisite to PRKCA-ABCB1 interaction, forming a tri-protein complex in drug-resistant CML cells that selectively enriches PRKCA and ABCB1 into exosomes. Mechanistically, exosomes enriched with both PRKCA and ABCB1 enhance fatty acid metabolism through PRKCA, activate the AGE-RAGE signaling pathway, and subsequently upregulate the transcription factors ETS1 and FOXA1. This process leads to increased expression of PRKCA and ABCB1 in drug-sensitive cells, which further contribute to drug efflux and drug resistance in CML cells. Clinically, plasma exosomal PRKCA and ABCB1 together accurately predict drug resistance in CML patients. CONCLUSIONS: PRKCA and ABCB1 dual-enriched exosomes are key drivers of drug resistance in CML patients, and exosomal PRKCA and ABCB1 may serve as diagnostic and therapeutic targets for CML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExosomesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveDrug Resistance, NeoplasmProtein Kinase C-alphaHumansATP Binding Cassette Transporter, Subfamily BAnimalsImatinib MesylateMiceDoxorubicinAntineoplastic AgentsCell Line, TumorProtein Kinase InhibitorsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

ABCB1Chronic myeloid leukemiaDrug resistanceExosomesPRKCA

Substanzen

ABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BProtein Kinase C-alphaImatinib MesylatePRKCA protein, humanDoxorubicinAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China.
  • Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.
  • Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
  • Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518107, China.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada; Department of Laboratory Medicine, LKSKI-Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Tor…
  • Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518107, China. Electronic address: chenchun@mail.sysu.edu.c…

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Li, F., Lin, J. F., Tian, P., Chen, H., Yang, Q., Guo, Q., Wang, J., He, Y., Chen, J., Hu, X., Li, C., Mai, W., Duan, M., Peng, M., Rousseau, Z., Chen, C., Ni, H., & Zhang, Q. (2026). PRKCA and ABCB1 dual-enriched exosomes are key drivers of drug resistance in chronic myeloid leukemia. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101421

Vancouver

Li F, Lin JF, Tian P, Chen H, Yang Q, Guo Q, et al. PRKCA and ABCB1 dual-enriched exosomes are key drivers of drug resistance in chronic myeloid leukemia. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101421

BibTeX
@article{Li2026,
  author = {Li, Fei and Lin, Jin-Fei and Tian, Peng and Chen, Haisheng and Yang, Qian and Guo, Qiqi and Wang, Jiasheng and He, Yue and Chen, Junru and Hu, Xiaojian and Li, Chunmou and Mai, Weitong and Duan, Menghan and Peng, Michael and Rousseau, Zackary and Chen, Chun and Ni, Heyu and Zhang, Qing},
  title = {PRKCA and ABCB1 dual-enriched exosomes are key drivers of drug resistance in chronic myeloid leukemia},
  journal = {Drug Resistance Updates},
  year = {2026},
  doi = {10.1016/j.drup.2026.101421}
}
Kostenlos starten →